Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Aug;22(8):1092-1093.
doi: 10.1016/S1473-3099(22)00282-1. Epub 2022 May 9.

What a second booster dose of mRNA COVID-19 vaccines tells us

Paul Loubet  1 , Odile Launay  2
Affiliations
Comment

What a second booster dose of mRNA COVID-19 vaccines tells us

Paul Loubet et al. Lancet Infect Dis. 2022 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

PL has received personal fees from AstraZeneca, GlaxoSmithKline, Janssen, Merck Sharp & Dohme, Pfizer, and Sanofi Pasteur, and non-financial support from Pfizer and Sanofi Pasteur. OL has received personal fees and non-financial support from Pfizer, Janssen, Sanofi Pasteur, Merck Sharp & Dohme, and GlaxoSmithKline.

Comment on

References

    1. Ferdinands JM, Rao S, Dixon BE, et al. Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance—VISION Network, 10 states, August 2021–January 2022. MMWR Morb Mortal Wkly Rep. 2022;71:255–263. - PMC - PubMed
    1. Bar-On YM, Goldberg Y, Mandel M, et al. Protection by a fourth dose of BNT162b2 against omicron in Israel. N Engl J Med. 2022 doi: 10.1056/NEJMoa2201570. published online April 5. - DOI - PMC - PubMed
    1. Magen O, Waxman JG, Makov-Assif M, et al. Fourth dose of BNT162b2 mRNA COVID-19 vaccine in a nationwide setting. N Engl J Med. 2022 doi: 10.1056/NEJMoa2201688. published online April 13. - DOI - PMC - PubMed
    1. Regev-Yochay G, Gonen T, Gilboa M, et al. Efficacy of a fourth dose of COVID-19 mRNA vaccine against omicron. N Engl J Med. 2022;386:1377–1380. - PMC - PubMed
    1. Munro APS, Feng S, Janani L, et al. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Lancet Infect Dis. 2022 doi: 10.1016/S1473-3099(22)00271-7. published online May 9. - DOI - PMC - PubMed